Literature DB >> 22137823

Hepatocellular carcinoma within a noncirrhotic, nonfibrotic, seronegative liver: surgical approaches and outcomes.

Alastair L Young1, Robert Adair, K Rajendra Prasad, Giles J Toogood, J Peter A Lodge.   

Abstract

BACKGROUND: Hepatocellular carcinoma (HCC) most commonly arises in patients with chronic liver disease. Data on outcomes after liver resection in patients with noncirrhotic, nonfibrotic, seronegative, referred to as a "normal" liver are limited. We aimed to investigate differences in prognostic factors and outcomes between patients presenting with HCC arising in "normal" liver (NLHCC) and that arising in "diseased" liver (DLHCC). STUDY
DESIGN: All patients undergoing resection for HCC between 1994 and 2008 were assessed. Multivariable analysis of clincopathologic data from the NLHCC group was performed by comparing them with data from the group who had surgery for DLHCC during this period.
RESULTS: During the 15-year study period, 142 patients underwent liver resection for HCC: 81 for NLHCC and 61 for DLHCC. NLHCCs were more often solitary but were larger and required more major resections. There was no significant difference in survival outcomes between patients who had NLHCC or DLHCC, with overall and recurrence-free 5-year survivals of 60% and 51% in NLHCC and 55% and 33% in DLHCC, respectively. In patients with NLHCC, significant factors predicting overall survival were blood transfusion requirement (p = 0.003) and age (p = 0.009), and the only significant factor at predicting recurrence-free survival was presence of multiple tumors (p = 0.025). In contrast, in DLHCC, the only significant prognostic variables were a preoperative tumor biopsy (p = 0.017) or a high neutrophil-to-lymphocyte ratio (p = 0.001), both of which predicted a poorer recurrence-free survival.
CONCLUSIONS: HCC presenting in patients with a normal background liver parenchyma appears to present a different spectrum of the disease. However, excellent outcomes can be achieved after liver resection, although this often requires the use of advanced techniques due to late presentation.
Copyright © 2012 American College of Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 22137823     DOI: 10.1016/j.jamcollsurg.2011.10.005

Source DB:  PubMed          Journal:  J Am Coll Surg        ISSN: 1072-7515            Impact factor:   6.113


  23 in total

Review 1.  Bridging to liver transplantation in HCC patients.

Authors:  Dagmar Kollmann; Nazia Selzner; Markus Selzner
Journal:  Langenbecks Arch Surg       Date:  2017-07-28       Impact factor: 3.445

2.  Recurrence patterns and prognostic factors in patients with hepatocellular carcinoma in noncirrhotic liver: a multi-institutional analysis.

Authors:  Dean J Arnaoutakis; Michael N Mavros; Feng Shen; Sorin Alexandrescu; Amin Firoozmand; Irinel Popescu; Matthew Weiss; Christopher L Wolfgang; Michael A Choti; Timothy M Pawlik
Journal:  Ann Surg Oncol       Date:  2014-01       Impact factor: 5.344

Review 3.  Treatment of hepatocellular carcinoma: a systematic review.

Authors:  Shibo Lin; Katrin Hoffmann; Peter Schemmer
Journal:  Liver Cancer       Date:  2012-11       Impact factor: 11.740

4.  The Impact of Tumor Size on Long-Term Survival Outcomes After Resection of Solitary Hepatocellular Carcinoma: Single-Institution Experience with 2558 Patients.

Authors:  Shin Hwang; Young-Joo Lee; Ki-Hun Kim; Chul-Soo Ahn; Deok-Bog Moon; Tae-Yong Ha; Gi-Won Song; Dong-Hwan Jung; Sung-Gyu Lee
Journal:  J Gastrointest Surg       Date:  2015-05-09       Impact factor: 3.452

Review 5.  Contrast-enhanced ultrasound for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease.

Authors:  Mirella Fraquelli; Tin Nadarevic; Agostino Colli; Cristina Manzotti; Vanja Giljaca; Damir Miletic; Davor Štimac; Giovanni Casazza
Journal:  Cochrane Database Syst Rev       Date:  2022-09-02

6.  Prognosis and predictors of surgical complications in hepatocellular carcinoma patients with or without cirrhosis after hepatectomy.

Authors:  Toru Mizuguchi; Masaki Kawamoto; Makoto Meguro; Yukio Nakamura; Shigenori Ota; Thomas T Hui; Koichi Hirata
Journal:  World J Surg       Date:  2013-06       Impact factor: 3.352

7.  Long-term survival with repeated resections of recurrent hepatocellular carcinoma in a non-cirrhotic liver: case report and brief review of the literature.

Authors:  Christopher Hadjittofi; Panagiotis G Athanasopoulos; Rahul S Koti; Sofia K Konstantinidou; Brian R Davidson
Journal:  Ann Transl Med       Date:  2016-03

8.  Hepatocellular carcinoma in patients with no identifiable risk factors.

Authors:  Caitlin A McIntyre; Joanne F Chou; Mithat Gonen; Jinru Shia; Maya Gambarin-Gelwan; Vinod P Balachandran; T Peter Kingham; Peter J Allen; Jeffrey A Drebin; William R Jarnagin; Michael I D'Angelica
Journal:  HPB (Oxford)       Date:  2020-06-24       Impact factor: 3.647

9.  Abdominal ultrasound and alpha-foetoprotein for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease.

Authors:  Agostino Colli; Tin Nadarevic; Damir Miletic; Vanja Giljaca; Mirella Fraquelli; Davor Štimac; Giovanni Casazza
Journal:  Cochrane Database Syst Rev       Date:  2021-04-15

10.  Diagnostic Value of Glypican3, Heat Shock Protein 70 and Glutamine Synthetase in Hepatocellular Carcinoma Arising in Cirrhotic and Non-Cirrhotic Livers.

Authors:  Preithy Uthamalingam; Ashim Das; Arunanshu Behra; Naveen Kalra; Yogesh Chawla
Journal:  J Clin Exp Hepatol       Date:  2017-10-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.